Slingluff, Craig L. Jr
Petroni, Gina R.
Olson, Walter C.
Smolkin, Mark E.
Chianese-Bullock, Kimberly A.
Mauldin, Ileana S.
Smith, Kelly T.
Deacon, Donna H.
Varhegyi, Nikole E.
Donnelly, Sean B.
Reed, Caroline M.
Scott, Kristy
Galeassi, Nadejda V.
Grosh, William W.
Funding for this research was provided by:
GlaxoSmithKline
National Cancer Institute (P30 CA44579, T32 CA009109)
Article History
Received: 10 August 2015
Accepted: 29 October 2015
First Online: 18 November 2015
Compliance with ethical standards
:
: Dr. Slingluff has the following relationships directly related to this work: The recombinant MAGE-A3 protein, overlapping peptides and AS15 were provided to the University of Virginia for this trial by GlaxoSmithKline, and the trial was funded largely by a grant to the University of Virginia from GlaxoSmithKline. The remaining authors have no conflicts.